Clinical trials: Dopamine Receptor Occupancy
Schizophrenia, Schizoaffective Disorder
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
Ziprasidone is recommended to be dosed twice daily for the treatment of schizophrenia, based on peripheral pharmacokinetics and a knowledge of its half life in plasma level (5-10 hours).
- Trial name
- NCT00818298
- Testing
- ziprazidone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Healthy Volunteers
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer [11C]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.
- Trial name
- Ph1PET UK Stdy (NCT06300580)
- Testing
- ABBV-932
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AbbVie
Antipsychotics, Cognition
Change in Brain Metabolism and Cognitive Function by Aripiprazole
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
- Conditions
- Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
- Trial name
- NCT01562808
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Smoking Cessation, Tobacco Use Cessation
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET
The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been…
- Trial name
- NCT01699828
- Testing
- Buspirone
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
This study will provide information regarding dopamine D2/D3 occupancy related with clinical/adverse effects in older people with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00825045
- Testing
- risperidone
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Centre for Addiction and Mental Health